Anastrozole or tamoxifen for DCIS?

Results of the first head-to-head trial of tamoxifen and anastrozole for hormone-receptor-positive DCIS show the treatments have similar efficacy but differing side effects.

Levels of recurrence were statistically no different between the two treatment groups over a median follow-up period of 7.2 years, delegates at 2015 San Antonio Breast Cancer Symposium were told.

But side effects differed: